## Appendix 1 - Version with markings to show changes made

- 21. (Amended once) A method for producing an immunoglobulin comprising:
  - a) providing
    - i) a host cell; and
  - ii) a vector comprising a first exogenous gene and a second exogenous gene, wherein said first exogenous gene encodes a first immunoglobulin chain and wherein said second exogenous gene encodes a second immunoglobulin chain and wherein said first and said second genes are separated by an internal ribosome entry site; and
- b) introducing said vector to said host cell under conditions such that said first immunoglobulin chain and said second immunoglobulin chain are expressed, wherein said first antibody chain and said second antibody chain are expressed at a ratio of about 0.9:1.1.

21. (Amended once) A method for producing an immunoglobylin comprising:

- a) providing
  - i) a host cell; and
- ii) a vector comprising a first exogenous gene and a second exogenous gene, wherein said first exogenous gene encodes a first immunoglobulin chain and wherein said second exogenous gene encodes a second immunoglobulin chain and wherein said first and said second genes are separated by an internal ribosome entry site; and
- b) introducing said vector to said host cell under conditions such that said first immunoglobulin chain and said second immunoglobulin chain are expressed, wherein said first antibody chain and said second antibody chain are expressed at a ratio of about 0.9:1.1.

## CONCLUSION

All grounds of rejection and objection of the Office Action of November 19, 2002, having been addressed, reconsideration of the application is respectfully requested. It is respectfully submitted that the invention as claimed fully meets all requirements and that the claims are worthy of allowance. Should the Examiner believe that a telephone interview would aid in the prosecution of this application, Applicant encourages the Examiner to call the undersigned collect at (608) 218-6900.

Dated: March 25, 2003

J. Mitchell Jones
Registration No. 44,174

MEDLEN & CARROLL, LLP 101 Howard Street, Suite 350 San Francisco, California 94105 608/218-6900

## Appendix 2 - Pending Claims

- 21. (Amended once) A method for producing an immunoglobulin comprising:
  - a) providing
    - i) a host cell; and
  - ii) a vector comprising a first exogenous gene and a second exogenous gene, wherein said first exogenous gene encodes a first immunoglobulin chain and wherein said second exogenous gene encodes a second immunoglobulin chain and wherein said first and said second genes are separated by an internal ribosome entry site; and
- b) introducing said vector to said host cell under conditions such that said first immunoglobulin chain and said second immunoglobulin chain are expressed, wherein said first antibody chain and said second antibody chain are expressed at a ratio of about 0.9:1.1.
- 22. The method of claim 21, wherein one of said first immunoglobulin chain and said second immunoglobulin chain is an immunoglobulin light chain and wherein the other of said first immunoglobulin chain and said second immunoglobulin chain is an immunoglobulin heavy chain.
- 23. The method of Claim 22, wherein said heavy chain is selected from the group consisting of  $\gamma$ ,  $\alpha$ ,  $\mu$ ,  $\delta$ , or  $\epsilon$  heavy chains.
- 24. The method of Claim 22, wherein said light chain is selected from the group consisting of  $\kappa$  and  $\lambda$  light chains.
- 25. The method of Claim 21, wherein said immunoglobulin is a secretory immunoglobulin.
- 26. The method of claim 21, wherein said vector is a retroviral vector.
- 27. The method of claim 21, wherein said vector further comprises a bovine alphalactalbumin signal peptide.
- 28. The method of claim 21, wherein said vector further comprises a bovine/human hybrid alpha-lactalbumin promoter.
- 31. The method of Claim 21, wherein said vector is selected from the group consisting of a retroviral vector and a plasmid vector.
- 32. The method of Claim 21, wherein said vector is a retroviral vector.
- 33. The method of Claim 32, wherein said retroviral vector is a pseudotyped retroviral vector.